Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061.
Saved in:
| Title: | Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061. |
|---|---|
| Authors: | Burkey BF; Zafgen, Inc., Boston, Massachusetts (B.F.B., N.C.H., M.W., T.E.H., J.E.V.) and InskeepDMPK, LLC (P.I.), East Lyme, Connecticut bburkey@zafgen.com., Hoglen NC; Zafgen, Inc., Boston, Massachusetts (B.F.B., N.C.H., M.W., T.E.H., J.E.V.) and InskeepDMPK, LLC (P.I.), East Lyme, Connecticut., Inskeep P; Zafgen, Inc., Boston, Massachusetts (B.F.B., N.C.H., M.W., T.E.H., J.E.V.) and InskeepDMPK, LLC (P.I.), East Lyme, Connecticut., Wyman M; Zafgen, Inc., Boston, Massachusetts (B.F.B., N.C.H., M.W., T.E.H., J.E.V.) and InskeepDMPK, LLC (P.I.), East Lyme, Connecticut., Hughes TE; Zafgen, Inc., Boston, Massachusetts (B.F.B., N.C.H., M.W., T.E.H., J.E.V.) and InskeepDMPK, LLC (P.I.), East Lyme, Connecticut., Vath JE; Zafgen, Inc., Boston, Massachusetts (B.F.B., N.C.H., M.W., T.E.H., J.E.V.) and InskeepDMPK, LLC (P.I.), East Lyme, Connecticut. |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2018 May; Vol. 365 (2), pp. 301-313. Date of Electronic Publication: 2018 Feb 28. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
